NCT00763412 - Pilot and Feasibility Study for the Treatment of Pre-diabetes in Patients With Cystic Fibrosis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

January 31, 2013

Study Completion Date

January 31, 2013

Conditions

Cystic Fibrosis Related DiabetesPancreatic Insufficiency

Interventions

DRUG

placebo

CF pancreatic insufficient patients with impaired glucose tolerance (IGT) or CFRD without fasting hyperglycemia (CFRD-No FH) by OGTT will be treated with placebo by taking 1 pill before each meal that contains more than 20 grams of carbohydrate 3-4 times a day for 2 years.

DRUG

repaglinide

CF pancreatic insufficient patients with impaired glucose tolerance (IGT) or CFRD without fasting hyperglycemia (CFRD-No FH) by OGTT will be treated with repaglinide 0.5 mg before each meal that contains more than 20 grams of carbohydrate 3-4 times a day for 2 years.

Trial Locations (1)

63110

Washington University School of Medicine, St Louis